{"name":"Novo Nordisk","slug":"novo-nordisk","ticker":"NVO","exchange":"NYSE","domain":"novonordisk.com","description":"Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.","hq":"Bagsværd, Denmark","founded":1923,"employees":"67900","ceo":"Lars Fruergaard Jørgensen","sector":"Big Pharma","stockPrice":46.12,"stockChange":-0.96,"stockChangePercent":-2.04,"marketCap":"$31.9B","metrics":{"revenue":51225393945.927345,"revenueGrowth":24,"grossMargin":83.2,"rdSpend":0,"netIncome":19058253188.373135,"cash":3379500759.007027,"dividendYield":3.83,"peRatio":10.7,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Ozempic","genericName":"semaglutide","slug":"semaglutide","revenue":27400000000,"yoyGrowth":0,"percentOfTotal":72.3},{"name":"Tresiba","genericName":"INSULIN DEGLUDEC","slug":"insulin-degludec","revenue":4500000000,"yoyGrowth":0,"percentOfTotal":11.9},{"name":"Victoza","genericName":"liraglutide","slug":"liraglutide","revenue":3200000000,"yoyGrowth":0,"percentOfTotal":8.4},{"name":"Novolog","genericName":"INSULIN ASPART","slug":"insulin-aspart","revenue":2800000000,"yoyGrowth":0,"percentOfTotal":7.4}],"timeline":[{"date":"1997-01-01","label":"Prandin first approved","drug":"Prandin","drugSlug":"repaglinide","type":"approval","sentiment":"positive"},{"date":"2000-01-01","label":"Novolog first approved","drug":"Novolog","drugSlug":"insulin-aspart","type":"approval","sentiment":"positive"},{"date":"2005-01-01","label":"Levemir first approved","drug":"Levemir","drugSlug":"insulin-detemir","type":"approval","sentiment":"positive"},{"date":"2015-01-01","label":"Tresiba first approved","drug":"Tresiba","drugSlug":"insulin-degludec","type":"approval","sentiment":"positive"},{"date":"2017-01-01","label":"Ozempic first approved","drug":"Ozempic","drugSlug":"semaglutide","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Sogroya first approved","drug":"Sogroya","drugSlug":"somapacitan","type":"approval","sentiment":"positive"},{"date":"2024-01-01","label":"Alhemo first approved","drug":"Alhemo","drugSlug":"concizumab","type":"approval","sentiment":"positive"},{"date":"2025-01-01","label":"Rivfloza first approved","drug":"Rivfloza","drugSlug":"nedosiran","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-02-21","label":"Alhemo PHASE3 readout","drug":"Alhemo","drugSlug":"concizumab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2037-01-09","label":"Victoza patent expiry (Method of Use)","drug":"Victoza","drugSlug":"liraglutide","type":"patent_expiry","sentiment":"negative"},{"date":"2037-07-09","label":"Victoza patent expiry (Compound)","drug":"Victoza","drugSlug":"liraglutide","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Ozempic patent cliff ($1.5B at risk)","drug":"Ozempic","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Victoza patent cliff ($500M at risk)","drug":"Victoza","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":37900000000,"percentOfTotal":100,"drugCount":41,"colorKey":"oncology","drugs":[{"name":"Ozempic","genericName":"semaglutide","slug":"semaglutide","indication":"Glycemic Control in Type 2 Diabetes","status":"marketed","revenue":27400000000},{"name":"Tresiba","genericName":"INSULIN DEGLUDEC","slug":"insulin-degludec","indication":"Diabetes mellitus","status":"marketed","revenue":4500000000},{"name":"Victoza","genericName":"liraglutide","slug":"liraglutide","indication":"Diabetes mellitus type 2","status":"marketed","revenue":3200000000},{"name":"Novolog","genericName":"INSULIN ASPART","slug":"insulin-aspart","indication":"Diabetes mellitus","status":"marketed","revenue":2800000000},{"name":"Prandin","genericName":"repaglinide","slug":"repaglinide","indication":"Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus","status":"marketed"},{"name":"Faster aspart","genericName":"Faster aspart","slug":"faster-aspart","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"NNC0487-0111","genericName":"NNC0487-0111","slug":"nnc0487-0111","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"NNC6019-0001","genericName":"NNC6019-0001","slug":"nnc6019-0001","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"insulin NPH","genericName":"insulin NPH","slug":"insulin-nph","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Basal insulin analogues","genericName":"Basal insulin analogues","slug":"basal-insulin-analogues","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"CagriSema","genericName":"CagriSema","slug":"cagrisema","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Faster-acting insulin aspart","genericName":"Faster-acting insulin aspart","slug":"faster-acting-insulin-aspart","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Fiasp®","genericName":"Fiasp®","slug":"fiasp","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"IGlar U100","genericName":"IGlar U100","slug":"iglar-u100","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"IcoSema","genericName":"IcoSema","slug":"icosema","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Insulin Glargine 100U/mL","genericName":"Insulin Glargine 100U/mL","slug":"insulin-glargine-100u-ml","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Insulin aspart (NovoRapid®)","genericName":"Insulin aspart (NovoRapid®)","slug":"insulin-aspart-novorapid","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin glargine U100","genericName":"Insulin glargine U100","slug":"insulin-glargine-u100","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin-Levemir","genericName":"Insulin-Levemir","slug":"insulin-levemir","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Levemir","genericName":"INSULIN DETEMIR","slug":"insulin-detemir","indication":"Diabetes mellitus","status":"marketed"},{"name":"NNC0365-3769 (Mim8)","genericName":"NNC0365-3769 (Mim8)","slug":"nnc0365-3769-mim8","indication":"Type 2 diabetes","status":"phase_3"},{"name":"NNC0365-3769 (Mim8) PPX","genericName":"NNC0365-3769 (Mim8) PPX","slug":"nnc0365-3769-mim8-ppx","indication":"Type 2 diabetes","status":"phase_3"},{"name":"NPH insulin","genericName":"NPH insulin","slug":"nph-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Placebo II (Semaglutide)","genericName":"Placebo II (Semaglutide)","slug":"placebo-ii-semaglutide","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Placebo cagrilintide","genericName":"Placebo cagrilintide","slug":"placebo-cagrilintide","indication":"Chronic weight management in adults with obesity or overweight with weight-related comorbidities (Phase 3)","status":"phase_3"},{"name":"Placebo insulin icodec","genericName":"Placebo insulin icodec","slug":"placebo-insulin-icodec","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Semaglutide B","genericName":"Semaglutide B","slug":"semaglutide-b","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Semaglutide J","genericName":"Semaglutide J","slug":"semaglutide-j","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"biphasic human insulin 30","genericName":"biphasic human insulin 30","slug":"biphasic-human-insulin-30","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"biphasic human insulin 50","genericName":"biphasic human insulin 50","slug":"biphasic-human-insulin-50","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"biphasic insulin aspart","genericName":"biphasic insulin aspart","slug":"biphasic-insulin-aspart","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"biphasic insulin aspart 30","genericName":"biphasic insulin aspart 30","slug":"biphasic-insulin-aspart-30","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"biphasic insulin aspart 50","genericName":"biphasic insulin aspart 50","slug":"biphasic-insulin-aspart-50","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"biphasic insulin aspart 70","genericName":"biphasic insulin aspart 70","slug":"biphasic-insulin-aspart-70","indication":"Type 1 diabetes","status":"phase_3"},{"name":"human insulin","genericName":"human insulin","slug":"human-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"human soluble insulin","genericName":"human soluble insulin","slug":"human-soluble-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"isophane human insulin","genericName":"isophane human insulin","slug":"isophane-human-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"oral anti-diabetic drug","genericName":"oral anti-diabetic drug","slug":"oral-anti-diabetic-drug","indication":"Type 2 diabetes","status":"phase_3"},{"name":"repaglinide and metformin combination tablet","genericName":"repaglinide and metformin combination tablet","slug":"repaglinide-and-metformin-combination-tablet","indication":"Type 2 diabetes","status":"phase_3"},{"name":"rosiglitazone and metformin combination tablet","genericName":"rosiglitazone and metformin combination tablet","slug":"rosiglitazone-and-metformin-combination-tablet","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"soluble human insulin","genericName":"soluble human insulin","slug":"soluble-human-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":38,"colorKey":"immunology","drugs":[{"name":"SNAC","genericName":"SNAC","slug":"snac","indication":"Other","status":"marketed"},{"name":"Semaglutide 2.4 mg","genericName":"Semaglutide 2.4 mg","slug":"semaglutide-2-4-mg","indication":"Other","status":"marketed"},{"name":"Semaglutide B 7 mg","genericName":"Semaglutide B 7 mg","slug":"semaglutide-b-7-mg","indication":"Other","status":"phase_1"},{"name":"Semaglutide L","genericName":"Semaglutide L","slug":"semaglutide-l","indication":"Other","status":"phase_1"},{"name":"Semaglutide 1.0 mg","genericName":"Semaglutide 1.0 mg","slug":"semaglutide-1-0-mg","indication":"Other","status":"marketed"},{"name":"Sogroya","genericName":"SOMAPACITAN","slug":"somapacitan","indication":"Growth failure due to inadequate GH secretion","status":"marketed"},{"name":"factor VIII","genericName":"factor VIII","slug":"factor-viii","indication":"Other","status":"marketed"},{"name":"glicazide","genericName":"glicazide","slug":"glicazide","indication":"Other","status":"marketed"},{"name":"148-0287-A-4.2mM-cartridge","genericName":"148-0287-A-4.2mM-cartridge","slug":"148-0287-a-4-2mm-cartridge","indication":"Other","status":"phase_1"},{"name":"ALHEMO","genericName":"CONCIZUMAB-MTCI","slug":"concizumab-mtci","indication":"Other","status":"marketed"},{"name":"BIAsp 30","genericName":"BIAsp 30","slug":"biasp-30","indication":"Other","status":"marketed"},{"name":"DPP-4 inhibitors","genericName":"DPP-4 inhibitors","slug":"dpp-4-inhibitors","indication":"Other","status":"marketed"},{"name":"EX1000","genericName":"EX1000","slug":"ex1000","indication":"Other","status":"phase_2"},{"name":"Eptacog Alfa","genericName":"EPTACOG ALFA (ACTIVATED)","slug":"eptacog-alfa-activated","indication":"Factor VII deficiency","status":"marketed"},{"name":"Esperoct","genericName":"Esperoct","slug":"esperoct","indication":"Hereditary factor VIII deficiency disease","status":"marketed"},{"name":"Exenatide-Bayetta","genericName":"Exenatide-Bayetta","slug":"exenatide-bayetta","indication":"Other","status":"marketed"},{"name":"Feiba VH","genericName":"Feiba VH","slug":"feiba-vh","indication":"Other","status":"marketed"},{"name":"Glucobay®","genericName":"Glucobay®","slug":"glucobay","indication":"Other","status":"marketed"},{"name":"Glurenorm®","genericName":"Glurenorm®","slug":"glurenorm","indication":"Other","status":"marketed"},{"name":"Insulin-Levemir and Exenatide-Bayetta","genericName":"Insulin-Levemir and Exenatide-Bayetta","slug":"insulin-levemir-and-exenatide-bayetta","indication":"Other","status":"marketed"},{"name":"NC0194-0499","genericName":"NC0194-0499","slug":"nc0194-0499","indication":"Other","status":"phase_1"},{"name":"NNC0385-0434 C","genericName":"NNC0385-0434 C","slug":"nnc0385-0434-c","indication":"Other","status":"phase_1"},{"name":"NNC0471-0119 D","genericName":"NNC0471-0119 D","slug":"nnc0471-0119-d","indication":"Other","status":"phase_1"},{"name":"NNC4004-0002","genericName":"NNC4004-0002","slug":"nnc4004-0002","indication":"Other","status":"phase_1"},{"name":"NNC6989-0001 A","genericName":"NNC6989-0001 A","slug":"nnc6989-0001-a","indication":"Other","status":"phase_1"},{"name":"Norditropin","genericName":"Norditropin","slug":"norditropin","indication":"Other","status":"marketed"},{"name":"Novoeight","genericName":"TUROCTOCOG ALFA","slug":"turoctocog-alfa","indication":"Hereditary factor VIII deficiency disease","status":"marketed"},{"name":"Novothirteen","genericName":"CATRIDECACOG","slug":"catridecacog","indication":"Hereditary factor XIII A subunit deficiency","status":"marketed"},{"name":"Placebo (Mim8)","genericName":"Placebo (Mim8)","slug":"placebo-mim8","indication":"Other","status":"phase_3"},{"name":"Placebo semaglutide","genericName":"Placebo semaglutide","slug":"placebo-semaglutide","indication":"Clinical trial control comparator (not a therapeutic indication)","status":"marketed"},{"name":"Rivfloza","genericName":"NEDOSIRAN","slug":"nedosiran","indication":"primary hyperoxaluria type 1","status":"marketed"},{"name":"SOGROYA","genericName":"SOMAPACITAN-BECO","slug":"somapacitan-beco","indication":"Growth failure due to inadequate GH secretion","status":"marketed"},{"name":"Semagludtide","genericName":"Semagludtide","slug":"semagludtide","indication":"Other","status":"phase_3"},{"name":"Trizepatide","genericName":"Trizepatide","slug":"trizepatide","indication":"Other","status":"phase_2"},{"name":"activated recombinant human factor VII","genericName":"activated recombinant human factor VII","slug":"activated-recombinant-human-factor-vii","indication":"Other","status":"marketed"},{"name":"biphasic human insulin","genericName":"biphasic human insulin","slug":"biphasic-human-insulin","indication":"Other","status":"marketed"},{"name":"liraglutide-depot","genericName":"liraglutide-depot","slug":"liraglutide-depot","indication":"Other","status":"phase_1"},{"name":"recombinant factor XIII","genericName":"recombinant factor XIII","slug":"recombinant-factor-xiii","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"Placebo (canagliflozin)","genericName":"Placebo (canagliflozin)","slug":"placebo-canagliflozin","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Placebo (ziltivekimab)","genericName":"Placebo (ziltivekimab)","slug":"placebo-ziltivekimab","indication":"Cardiovascular disease with elevated inflammatory markers (Phase 3 development)","status":"phase_3"},{"name":"Placebo I (Semaglutide)","genericName":"Placebo I (Semaglutide)","slug":"placebo-i-semaglutide","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Ziltivekimab C","genericName":"Ziltivekimab C","slug":"ziltivekimab-c","indication":"Reduction of cardiovascular risk in patients with coronary artery disease and elevated inflammatory markers","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Alhemo","genericName":"CONCIZUMAB","slug":"concizumab","indication":"hemophilia A (congenital factor VIII deficiency)","status":"marketed"},{"name":"Eptacog alfa (NovoSeven)","genericName":"Eptacog alfa (NovoSeven)","slug":"eptacog-alfa-novoseven","indication":"Hemophilia A with inhibitors","status":"marketed"},{"name":"Turoctocog alfa pegol (N8-GP)","genericName":"Turoctocog alfa pegol (N8-GP)","slug":"turoctocog-alfa-pegol-n8-gp","indication":"Hemophilia A (prevention and treatment of bleeding episodes)","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"Etavopivat A","genericName":"Etavopivat A","slug":"etavopivat-a","indication":"Sickle cell disease","status":"phase_3"},{"name":"Etavopivat B","genericName":"Etavopivat B","slug":"etavopivat-b","indication":"Sickle cell disease (vaso-occlusive crises and hemolysis reduction)","status":"phase_3"},{"name":"Etavopivat C","genericName":"Etavopivat C","slug":"etavopivat-c","indication":"Sickle cell disease (to reduce hemolysis and vaso-occlusive crises)","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"Ziltivekimab B","genericName":"Ziltivekimab B","slug":"ziltivekimab-b","indication":"Treatment of generalized pustular psoriasis","status":"phase_3"}]}],"pipeline":[{"name":"Ozempic","genericName":"semaglutide","slug":"semaglutide","phase":"marketed","mechanism":"Semaglutide, a GLP-1 analogue, lowers blood glucose by stimulating insulin and inhibiting glucagon secretion in a glucose-dependent manner, and delays gastric emptying.","indications":["Glycemic Control in Type 2 Diabetes","Reduction of CV Risk in Type 2 Diabetes"],"catalyst":""},{"name":"Tresiba","genericName":"INSULIN DEGLUDEC","slug":"insulin-degludec","phase":"marketed","mechanism":"Tresiba works by binding to the insulin receptor, mimicking the action of natural insulin to lower blood sugar levels.","indications":["Diabetes mellitus"],"catalyst":""},{"name":"Victoza","genericName":"liraglutide","slug":"liraglutide","phase":"marketed","mechanism":"Glucagon-like peptide 1 receptor","indications":["Diabetes mellitus type 2","Weight loss"],"catalyst":""},{"name":"Novolog","genericName":"INSULIN ASPART","slug":"insulin-aspart","phase":"marketed","mechanism":"Novolog works by binding to the insulin receptor, triggering a cascade of cellular responses that lower blood glucose levels.","indications":["Diabetes mellitus"],"catalyst":""},{"name":"Prandin","genericName":"repaglinide","slug":"repaglinide","phase":"marketed","mechanism":"Repaglinide lowers blood glucose levels by stimulating insulin release from the pancreas through ATP-dependent potassium channel blockade.","indications":["Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus","Not for treatment of type 1 diabetes mellitus","Not for treatment of diabetic ketoacidosis"],"catalyst":""},{"name":"SNAC","genericName":"SNAC","slug":"snac","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Semaglutide 2.4 mg","genericName":"Semaglutide 2.4 mg","slug":"semaglutide-2-4-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Semaglutide B 7 mg","genericName":"Semaglutide B 7 mg","slug":"semaglutide-b-7-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Semaglutide L","genericName":"Semaglutide L","slug":"semaglutide-l","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Faster aspart","genericName":"Faster aspart","slug":"faster-aspart","phase":"phase_3","mechanism":"Faster aspart is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"NNC0487-0111","genericName":"NNC0487-0111","slug":"nnc0487-0111","phase":"phase_3","mechanism":"NNC0487-0111 is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"NNC6019-0001","genericName":"NNC6019-0001","slug":"nnc6019-0001","phase":"phase_3","mechanism":"NNC6019-0001 is a glucagon receptor antagonist that blocks glucagon signaling to reduce hepatic glucose production and improve glycemic control.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Semaglutide 1.0 mg","genericName":"Semaglutide 1.0 mg","slug":"semaglutide-1-0-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sogroya","genericName":"SOMAPACITAN","slug":"somapacitan","phase":"marketed","mechanism":"Sogroya works by binding to the growth hormone receptor, mimicking the action of growth hormone and stimulating growth and development.","indications":["Growth failure due to inadequate GH secretion","Short stature, SGA without catch-up growth","Growth failure associated with Noonan syndrome","Idiopathic Short Stature","Growth hormone deficiency in adults"],"catalyst":""},{"name":"factor VIII","genericName":"factor VIII","slug":"factor-viii","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"glicazide","genericName":"glicazide","slug":"glicazide","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"insulin NPH","genericName":"insulin NPH","slug":"insulin-nph","phase":"marketed","mechanism":"Insulin NPH is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"148-0287-A-4.2mM-cartridge","genericName":"148-0287-A-4.2mM-cartridge","slug":"148-0287-a-4-2mm-cartridge","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALHEMO","genericName":"CONCIZUMAB-MTCI","slug":"concizumab-mtci","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Alhemo","genericName":"CONCIZUMAB","slug":"concizumab","phase":"marketed","mechanism":"Alhemo works by blocking the activation of blood clotting factors to prevent excessive bleeding in people with hemophilia.","indications":["hemophilia A (congenital factor VIII deficiency)","hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors","hemophilia B (congenital factor IX deficiency)","hemophilia B (congenital factor IX deficiency) with or without FIX inhibitors"],"catalyst":""},{"name":"BIAsp 30","genericName":"BIAsp 30","slug":"biasp-30","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Basal insulin analogues","genericName":"Basal insulin analogues","slug":"basal-insulin-analogues","phase":"marketed","mechanism":"Basal insulin analogues are long-acting insulin formulations that bind to insulin receptors to promote glucose uptake and utilization, providing steady background insulin coverage for blood glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"CagriSema","genericName":"CagriSema","slug":"cagrisema","phase":"phase_3","mechanism":"CagriSema is a dual GLP-1/GCG receptor agonist that activates both glucagon-like peptide-1 and glucagon receptors to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management (in development)"],"catalyst":""},{"name":"DPP-4 inhibitors","genericName":"DPP-4 inhibitors","slug":"dpp-4-inhibitors","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EX1000","genericName":"EX1000","slug":"ex1000","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Eptacog Alfa","genericName":"EPTACOG ALFA (ACTIVATED)","slug":"eptacog-alfa-activated","phase":"marketed","mechanism":"Recombinant protein","indications":["Factor VII deficiency","Glanzmann's thrombasthenia","Hereditary factor IX deficiency disease","Hereditary factor VIII deficiency disease"],"catalyst":""},{"name":"Eptacog alfa (NovoSeven)","genericName":"Eptacog alfa (NovoSeven)","slug":"eptacog-alfa-novoseven","phase":"marketed","mechanism":"Eptacog alfa is a recombinant Factor VIIa that bypasses upstream coagulation defects by directly activating Factor X on the tissue factor pathway to initiate thrombin generation and hemostasis.","indications":["Hemophilia A with inhibitors","Hemophilia B with inhibitors","Factor VII deficiency","Glanzmann thrombasthenia with refractoriness to platelet transfusions","Acquired hemophilia"],"catalyst":""},{"name":"Esperoct","genericName":"Esperoct","slug":"esperoct","phase":"marketed","mechanism":"Small molecule","indications":["Hereditary factor VIII deficiency disease"],"catalyst":""},{"name":"Etavopivat A","genericName":"Etavopivat A","slug":"etavopivat-a","phase":"phase_3","mechanism":"Etavopivat activates the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway to increase fetal hemoglobin (HbF) production and reduce hemolysis in patients with sickle cell disease.","indications":["Sickle cell disease"],"catalyst":""},{"name":"Etavopivat B","genericName":"Etavopivat B","slug":"etavopivat-b","phase":"phase_3","mechanism":"Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism.","indications":["Sickle cell disease (vaso-occlusive crises and hemolysis reduction)"],"catalyst":""},{"name":"Etavopivat C","genericName":"Etavopivat C","slug":"etavopivat-c","phase":"phase_3","mechanism":"Etavopivat activates the pyruvate dehydrogenase kinase (PDK) inhibitor pathway to reduce hemolysis in sickle cell disease by modulating red blood cell metabolism.","indications":["Sickle cell disease (to reduce hemolysis and vaso-occlusive crises)"],"catalyst":""},{"name":"Exenatide-Bayetta","genericName":"Exenatide-Bayetta","slug":"exenatide-bayetta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Faster-acting insulin aspart","genericName":"Faster-acting insulin aspart","slug":"faster-acting-insulin-aspart","phase":"phase_3","mechanism":"Faster-acting insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Feiba VH","genericName":"Feiba VH","slug":"feiba-vh","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fiasp®","genericName":"Fiasp®","slug":"fiasp","phase":"marketed","mechanism":"Fiasp is a rapid-acting insulin analog that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Glucobay®","genericName":"Glucobay®","slug":"glucobay","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Glurenorm®","genericName":"Glurenorm®","slug":"glurenorm","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IGlar U100","genericName":"IGlar U100","slug":"iglar-u100","phase":"marketed","mechanism":"IGlar U100 is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"IcoSema","genericName":"IcoSema","slug":"icosema","phase":"phase_3","mechanism":"IcoSema is a dual GLP-1/GIP receptor agonist that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors to improve glycemic control and promote weight loss.","indications":["Type 2 diabetes mellitus","Obesity or weight management"],"catalyst":""},{"name":"Insulin Glargine 100U/mL","genericName":"Insulin Glargine 100U/mL","slug":"insulin-glargine-100u-ml","phase":"phase_3","mechanism":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin aspart (NovoRapid®)","genericName":"Insulin aspart (NovoRapid®)","slug":"insulin-aspart-novorapid","phase":"marketed","mechanism":"Insulin aspart is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin glargine U100","genericName":"Insulin glargine U100","slug":"insulin-glargine-u100","phase":"marketed","mechanism":"Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin-Levemir","genericName":"Insulin-Levemir","slug":"insulin-levemir","phase":"marketed","mechanism":"Insulin detemir is a long-acting basal insulin that binds to the insulin receptor to facilitate glucose uptake and utilization in peripheral tissues while suppressing hepatic glucose production.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin-Levemir and Exenatide-Bayetta","genericName":"Insulin-Levemir and Exenatide-Bayetta","slug":"insulin-levemir-and-exenatide-bayetta","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Levemir","genericName":"INSULIN DETEMIR","slug":"insulin-detemir","phase":"marketed","mechanism":"Levemir works by binding to the insulin receptor, triggering a response that lowers blood sugar levels.","indications":["Diabetes mellitus"],"catalyst":""},{"name":"NC0194-0499","genericName":"NC0194-0499","slug":"nc0194-0499","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NNC0365-3769 (Mim8)","genericName":"NNC0365-3769 (Mim8)","slug":"nnc0365-3769-mim8","phase":"phase_3","mechanism":"Mim8 is a glucagon-like peptide-1 (GLP-1) receptor agonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"NNC0365-3769 (Mim8) PPX","genericName":"NNC0365-3769 (Mim8) PPX","slug":"nnc0365-3769-mim8-ppx","phase":"phase_3","mechanism":"Mim8 PPX is a glucagon-like peptide-1 (GLP-1) receptor agonist.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"NNC0385-0434 C","genericName":"NNC0385-0434 C","slug":"nnc0385-0434-c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NNC0471-0119 D","genericName":"NNC0471-0119 D","slug":"nnc0471-0119-d","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NNC4004-0002","genericName":"NNC4004-0002","slug":"nnc4004-0002","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NNC6989-0001 A","genericName":"NNC6989-0001 A","slug":"nnc6989-0001-a","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"NPH insulin","genericName":"NPH insulin","slug":"nph-insulin","phase":"marketed","mechanism":"NPH insulin is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Norditropin","genericName":"Norditropin","slug":"norditropin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Novoeight","genericName":"TUROCTOCOG ALFA","slug":"turoctocog-alfa","phase":"marketed","mechanism":"Recombinant protein","indications":["Hereditary factor VIII deficiency disease"],"catalyst":""},{"name":"Novothirteen","genericName":"CATRIDECACOG","slug":"catridecacog","phase":"marketed","mechanism":"Recombinant protein","indications":["Hereditary factor XIII A subunit deficiency"],"catalyst":""},{"name":"Placebo (Mim8)","genericName":"Placebo (Mim8)","slug":"placebo-mim8","phase":"phase_3","mechanism":"Placebo (Mim8) is an inert control substance used in clinical trials to establish baseline efficacy and safety comparisons.","indications":[],"catalyst":""},{"name":"Placebo (canagliflozin)","genericName":"Placebo (canagliflozin)","slug":"placebo-canagliflozin","phase":"phase_3","mechanism":"Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose.","indications":["Type 2 diabetes mellitus","Diabetic kidney disease","Heart failure with reduced ejection fraction"],"catalyst":""},{"name":"Placebo (ziltivekimab)","genericName":"Placebo (ziltivekimab)","slug":"placebo-ziltivekimab","phase":"phase_3","mechanism":"Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation.","indications":["Cardiovascular disease with elevated inflammatory markers (Phase 3 development)"],"catalyst":""},{"name":"Placebo I (Semaglutide)","genericName":"Placebo I (Semaglutide)","slug":"placebo-i-semaglutide","phase":"phase_3","mechanism":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.","indications":["Type 2 diabetes mellitus","Chronic weight management in adults with obesity or overweight with weight-related comorbidities","Cardiovascular risk reduction in patients with type 2 diabetes"],"catalyst":""},{"name":"Placebo II (Semaglutide)","genericName":"Placebo II (Semaglutide)","slug":"placebo-ii-semaglutide","phase":"phase_3","mechanism":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.","indications":["Type 2 diabetes mellitus","Chronic weight management in obese or overweight patients"],"catalyst":""},{"name":"Placebo cagrilintide","genericName":"Placebo cagrilintide","slug":"placebo-cagrilintide","phase":"phase_3","mechanism":"Cagrilintide is an amylin receptor agonist that slows gastric emptying and promotes satiety to reduce appetite and food intake.","indications":["Chronic weight management in adults with obesity or overweight with weight-related comorbidities (Phase 3)"],"catalyst":""},{"name":"Placebo insulin icodec","genericName":"Placebo insulin icodec","slug":"placebo-insulin-icodec","phase":"phase_3","mechanism":"Insulin icodec is a long-acting basal insulin analog that binds to the insulin receptor to regulate blood glucose by promoting glucose uptake and storage.","indications":["Type 2 diabetes mellitus","Type 1 diabetes mellitus"],"catalyst":""},{"name":"Placebo semaglutide","genericName":"Placebo semaglutide","slug":"placebo-semaglutide","phase":"marketed","mechanism":"Placebo semaglutide is an inactive formulation containing no active pharmaceutical ingredient and produces no pharmacological effect.","indications":["Clinical trial control comparator (not a therapeutic indication)"],"catalyst":""},{"name":"Rivfloza","genericName":"NEDOSIRAN","slug":"nedosiran","phase":"marketed","mechanism":"Nedosiran, a GalNAc-conjugated siRNA, binds to ASGPR on hepatocytes, degrades LDHA mRNA, reducing hepatic LDH and oxalate production.","indications":["primary hyperoxaluria type 1","primary hyperoxaluria type 1"],"catalyst":""},{"name":"SOGROYA","genericName":"SOMAPACITAN-BECO","slug":"somapacitan-beco","phase":"marketed","mechanism":"Growth hormone receptor","indications":["Growth failure due to inadequate GH secretion","Short stature SGA without catch-up growth","Growth failure associated with Noonan syndrome","Idiopathic Short Stature","Replacement of endogenous GH in GHD adults"],"catalyst":""},{"name":"Semagludtide","genericName":"Semagludtide","slug":"semagludtide","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Semaglutide B","genericName":"Semaglutide B","slug":"semaglutide-b","phase":"phase_3","mechanism":"Semaglutide B is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1 to regulate blood sugar levels.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Semaglutide J","genericName":"Semaglutide J","slug":"semaglutide-j","phase":"phase_3","mechanism":"Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, promote satiety, and slow gastric emptying.","indications":["Type 2 diabetes mellitus","Chronic weight management in adults with obesity or overweight"],"catalyst":""},{"name":"Trizepatide","genericName":"Trizepatide","slug":"trizepatide","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Turoctocog alfa pegol (N8-GP)","genericName":"Turoctocog alfa pegol (N8-GP)","slug":"turoctocog-alfa-pegol-n8-gp","phase":"phase_3","mechanism":"Turoctocog alfa pegol is a recombinant human coagulation factor VIII with extended half-life achieved through PEGylation, which replaces deficient clotting factor in hemophilia A patients.","indications":["Hemophilia A (prevention and treatment of bleeding episodes)"],"catalyst":""},{"name":"Ziltivekimab B","genericName":"Ziltivekimab B","slug":"ziltivekimab-b","phase":"phase_3","mechanism":"Ziltivekimab B is an interleukin-1 beta (IL-1β) inhibitor.","indications":["Treatment of generalized pustular psoriasis"],"catalyst":""},{"name":"Ziltivekimab C","genericName":"Ziltivekimab C","slug":"ziltivekimab-c","phase":"phase_3","mechanism":"Ziltivekimab is a monoclonal antibody that inhibits interleukin-6 (IL-6) signaling to reduce inflammation and cardiovascular risk.","indications":["Reduction of cardiovascular risk in patients with coronary artery disease and elevated inflammatory markers"],"catalyst":""},{"name":"activated recombinant human factor VII","genericName":"activated recombinant human factor VII","slug":"activated-recombinant-human-factor-vii","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"biphasic human insulin","genericName":"biphasic human insulin","slug":"biphasic-human-insulin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"biphasic human insulin 30","genericName":"biphasic human insulin 30","slug":"biphasic-human-insulin-30","phase":"marketed","mechanism":"Biphasic human insulin 30 is a premixed insulin formulation that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"biphasic human insulin 50","genericName":"biphasic human insulin 50","slug":"biphasic-human-insulin-50","phase":"marketed","mechanism":"Biphasic human insulin 50 is a combination insulin product that provides both rapid-acting and long-acting insulin coverage to regulate blood glucose levels in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"biphasic insulin aspart","genericName":"biphasic insulin aspart","slug":"biphasic-insulin-aspart","phase":"marketed","mechanism":"Biphasic insulin aspart is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in cells, with a biphasic formulation providing both immediate and intermediate insulin coverage.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"biphasic insulin aspart 30","genericName":"biphasic insulin aspart 30","slug":"biphasic-insulin-aspart-30","phase":"marketed","mechanism":"Biphasic insulin aspart 30 is a premixed insulin that combines rapid-acting insulin aspart with intermediate-acting insulin to provide both immediate and sustained blood glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"biphasic insulin aspart 50","genericName":"biphasic insulin aspart 50","slug":"biphasic-insulin-aspart-50","phase":"marketed","mechanism":"Biphasic insulin aspart 50 is a premixed insulin formulation that provides rapid-acting insulin aspart combined with intermediate-acting insulin to control blood glucose in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"biphasic insulin aspart 70","genericName":"biphasic insulin aspart 70","slug":"biphasic-insulin-aspart-70","phase":"phase_3","mechanism":"Biphasic insulin aspart 70 works by mimicking the body's natural insulin production to regulate blood sugar levels.","indications":["Type 1 diabetes","Type 2 diabetes"],"catalyst":""},{"name":"human insulin","genericName":"human insulin","slug":"human-insulin","phase":"marketed","mechanism":"Human insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus (when oral agents or other therapies are insufficient)"],"catalyst":""},{"name":"human soluble insulin","genericName":"human soluble insulin","slug":"human-soluble-insulin","phase":"marketed","mechanism":"Human soluble insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"isophane human insulin","genericName":"isophane human insulin","slug":"isophane-human-insulin","phase":"marketed","mechanism":"Isophane human insulin is an intermediate-acting insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"liraglutide-depot","genericName":"liraglutide-depot","slug":"liraglutide-depot","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"oral anti-diabetic drug","genericName":"oral anti-diabetic drug","slug":"oral-anti-diabetic-drug","phase":"phase_3","mechanism":"Works by stimulating the release of insulin from the pancreas.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"recombinant factor XIII","genericName":"recombinant factor XIII","slug":"recombinant-factor-xiii","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"repaglinide and metformin combination tablet","genericName":"repaglinide and metformin combination tablet","slug":"repaglinide-and-metformin-combination-tablet","phase":"phase_3","mechanism":"Repaglinide stimulates insulin secretion from the pancreas, while metformin decreases glucose production in the liver and increases insulin sensitivity.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"rosiglitazone and metformin combination tablet","genericName":"rosiglitazone and metformin combination tablet","slug":"rosiglitazone-and-metformin-combination-tablet","phase":"phase_3","mechanism":"Rosiglitazone improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), while metformin reduces hepatic glucose production and improves peripheral glucose uptake.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"soluble human insulin","genericName":"soluble human insulin","slug":"soluble-human-insulin","phase":"marketed","mechanism":"Soluble human insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[{"date":"2023-02-01","type":"earnings","headline":"Novo Nordisk reports strong Q4 2022 results","summary":"Novo Nordisk reported strong Q4 2022 results, driven by the continued success of Ozempic and other diabetes products.","drugName":"","sentiment":"positive"},{"date":"2022-12-15","type":"deal","headline":"Novo Nordisk partners with Eli Lilly to develop new diabetes treatments","summary":"Novo Nordisk has partnered with Eli Lilly to develop new diabetes treatments, expanding its presence in the diabetes care market.","drugName":"","sentiment":"neutral"},{"date":"2022-09-02","type":"regulatory","headline":"FDA approves Novo Nordisk's Wegovy for chronic weight management","summary":"The FDA has approved Novo Nordisk's Wegovy (semaglutide) for chronic weight management in adults with obesity or overweight with at least one weight-related condition.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTFByWnV2VTNhSENZR1hIRGItWVhrT3lrNlZqemhPRURPdG8yc054MFh5YlRCZGtQeUwyQzF0eENCVXl0ZDFsUkR0WEw2LXcwNXhLZFZScTFTSzQ?oc=5","date":"2026-04-02","type":"pipeline","source":"Britannica","summary":"Novo Nordisk A/S | History, Structure, Products & Facts | Britannica Money - Britannica","headline":"Novo Nordisk A/S | History, Structure, Products & Facts | Britannica Money","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPTjVoZVlRdlQ2QzlCTnhMM1dxd0k3QnRaZFlnWVVHRGhKampMUkhmTWhUd2FERG5XQWJ2dl9ZVGd4VFVRTWFRUnNIamMxRVN1NFdDa1pBUE53eTl3a0V5VzhNSjg2NzRJZHZ0dUxaNGxxVDFQaVEzT1diMnM3VjBJRkhpVk9aSUZnNXh3akl5TXpQb2NscXR0YjhVeEFXNTk5aV9pWHY2eU40SXZTQWo0Z2d4WGNjOGxFdkR5eTNkNA?oc=5","date":"2026-03-22","type":"regulatory","source":"AD HOC NEWS","summary":"Novo Nordisk A/S stock faces FDA warnings on GLP-1 drugs amid rising competition pressures - AD HOC NEWS","headline":"Novo Nordisk A/S stock faces FDA warnings on GLP-1 drugs amid rising competition pressures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxOVVRUTWFQMF94SWNlMU9ybjVxRXZXcER6TGVrU2RYT0V4S0JuNzZHUUFaWUV4TkN5eUtVY0JtczBPSzBmS0xSaUJvN0F0WkhtY2JIbkFZaHZ3NFU0YzNFLXNBem5sMW5qWFprRzhTWnpDbGtuUURqLVJKWnhGSnVqM2RrY21VYjY1YkdUaW5SdkVJZXQ2aEFYQUd6cm9aeXR4LU0xTWRRclhZeFEzeW9rNnRFZ2ZSNzlWNE1sbDhVYVg?oc=5","date":"2026-03-18","type":"regulatory","source":"AD HOC NEWS","summary":"Novo Nordisk A/S stock faces pressure from FDA warning on semaglutide reporting and Bernstein Underp - AD HOC NEWS","headline":"Novo Nordisk A/S stock faces pressure from FDA warning on semaglutide reporting and Bernstein Underp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNdnhRNU9ydGREekZhdFpDdDZxMjVqd3hGZUVjT1hsOEhQM2U2OVRUZlhSN0o2Y3A4UU9DOG80eDY2QUZ3bHhxRV9oVTlfV3JQYU5TeE9fUHZLdEJyU00ydGwwdnVRVFBKS2o1cXlseEJmWGYwYUo5WFdzWEZxdjJlRA?oc=5","date":"2026-03-10","type":"pipeline","source":"TradingKey","summary":"Novo Nordisk A/S Stock (NVO) Moved Down by 3.13% on Mar 10: Facts Behind the Movement - TradingKey","headline":"Novo Nordisk A/S Stock (NVO) Moved Down by 3.13% on Mar 10: Facts Behind the Movement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPREJzTW1TYmdZUXV4N2o1RzBRMG0wY1hLRkg1M21OaF9wUXhKR3VZVC1SRGZOYVYxMlIyYTZWUDNKclJXM2Y1dEp5MG9na3V6b1I2UGZVTzI3MFFzcldJYW05VjFUMW9XNjA0YkN2Q2V3VDh1WDJQc3U0QkRzUzBONVFqRjJiYTFMSUFsUWxYaXFidk53a0pFMUpLdDBuaTRCWUEySWxFeUpPXzhxaXdPc2FVc0Y2VmZXTUhyeTRsU2RGb2ZUczB3RXZIYw?oc=5","date":"2026-03-04","type":"pipeline","source":"Stock Titan","summary":"Novo Nordisk (IPHA) files 7.82% stake disclosure in Innate Pharma (13G/A) - Stock Titan","headline":"Novo Nordisk (IPHA) files 7.82% stake disclosure in Innate Pharma (13G/A)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTFAwdzluRWF2NzA1WWl2elJjNWRWOGFwRVlaRVVTcE5WeG1VUllzTTllR3hYd2JBRWdvUkc0ZHhTV0hwbGg4eUU1akI1WlhkNTRWd29wTElpSHZzNnlKUTZyRnFrTVlPVTdKSEVYZHlrU3Zvb3JnMUdZbXVIa2ZGZ1U?oc=5","date":"2026-01-16","type":"pipeline","source":"Yahoo Finance","summary":"Novo Nordisk (NVO) is “in a Battle,” Says Jim Cramer - Yahoo Finance","headline":"Novo Nordisk (NVO) is “in a Battle,” Says Jim Cramer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE80U1c4Szg1Sy0wSW16T0hFcURxQmQ1UDZpVjduR29ZanZ5MTFBNWlFbExkbmJ5b3pqS1FxcE1zYXZNdW9Ua3JMMmtjcFVnVVk0OHh2ckJ3dnVKSDBSTXYxRFhuZ25JSUVvSVlHbEYwdTY0LVFv?oc=5","date":"2026-01-12","type":"pipeline","source":"Market.us","summary":"Novo Nordisk Statistics and Facts - Market.us","headline":"Novo Nordisk Statistics and Facts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNTXNZVUsxaV9fUl9Ka1RhOEdHYXlWOUZZcDdqV1VWNThFU2tqRUhweS1IX01rMFd6NlB5ZmNxdXlFSW10RmFtWVZ4Mk1vajh6RTJxQXZOeDdfNkV5UzlnRlpPYVljdExFS0FZSXBnc1hpQjNIQkZJMnQ5NFVHeUZKYXkzaUtjZkRpRWo5eEFXXzd0eU0?oc=5","date":"2025-12-12","type":"pipeline","source":"Finviz","summary":"Novo Nordisk (NVO) Experiences Muted Sentiment From Analysts - Finviz","headline":"Novo Nordisk (NVO) Experiences Muted Sentiment From Analysts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPOHBlZmNyMzBoMGF3dU9aUzB4TVFPRGl4OTc3Ulo1WmZpV3Z5U1FZYjNVS2Vmb3Nfdl9yQ2Q0aGNMTXFuMmRoWDJYS0l3VS1DV19hdC1Bdk45YnJOa2lKZWxFQjRHRnE0TEpmVkFnNWxKRTNwWktJSVdobVpGS2VEZ2RZdjNQbk45a0wwNVlkdC00ZUNteE9GdDhJTkNneUtmdHNQRnIyVUw1U0h3YXc?oc=5","date":"2025-11-20","type":"pipeline","source":"Bloomberg.com","summary":"Novo Nordisk Powers Denmark’s Fastest Growth in Four Years - Bloomberg.com","headline":"Novo Nordisk Powers Denmark’s Fastest Growth in Four Years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOZ1NwMDRXUlBnSkVQZi12ZnhmUy1OTTRmcERxU0tfckwzUTZaOW1DUmxCOTYxU2tERjBvUWdRYmwtaExlNGdtdy00WG9TMTRwazdwSkRuNzZfblA2OGhkeXktYnJ2RlRrTE5ETG9zT2RCbWJibm5zU3JVNTVybW43SC1tZE45ZTN6ZjlmV1FmY3VnUTE1QTNFWC0zNEpnR3g3NkZkdXEwLWxpdlNIaVFYMWtR?oc=5","date":"2025-10-23","type":"deal","source":"Bloomberg.com","summary":"Novo Gives Top IR Job to Analyst With 15 Years of Buy Ratings - Bloomberg.com","headline":"Novo Gives Top IR Job to Analyst With 15 Years of Buy Ratings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQTm1GTWJteXJUcEVhTUItOHNOdHNqN0x2eWJoa2kxVE9XVXFNZjN2NnFhVGFvOW95d0RzdnF5MC1lRm5YeWFXYnZhUG5QY2trR0Vqdl9qMVJwejMyWnc5TWxKQWdqMzVvbEJxTFR6UGhvLThvZU1MYVhBd0N2ZEUyYkZZSTdkRlBrcXhFT1J5ekZYT3R5dU0wVVl3Ykw5alFkSnpMVDczWDJDWVJFVUhzQl9rMWxMTUFWZVVDQmpDQQ?oc=5","date":"2025-09-08","type":"pipeline","source":"Seeking Alpha","summary":"Novo Nordisk: A Pharma Leader With Growth Potential And Portfolio-Defensive Appeal - Seeking Alpha","headline":"Novo Nordisk: A Pharma Leader With Growth Potential And Portfolio-Defensive Appeal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOMHZkdER5WWJhdFRYSjlmWE84Tm9YdFoxSXFobU0yWGRLSEZtY2pZN2Fqam1nVFVlcWRnVzRqS2pFOHpYeUNtbUhMMGRhZ05Wa2FuS3d3WnpuY29hQXhlR1FQTURhdEZwenFFQmpZMmk2MVdqaUhRYnlDTVdlcHNzdW00VHZXS1Rlb2ZvR0RRUEFpNEQ0ZmQ0cnJEX1E4LXFVRGZJQTFMQ3hTLUxmekUwdzM3X1g4RXJJZTlBcUo5bkc1Zw?oc=5","date":"2025-06-27","type":"pipeline","source":"Reuters","summary":"Novo Nordisk says WeightWatchers will sell Wegovy, announces $299 price - Reuters","headline":"Novo Nordisk says WeightWatchers will sell Wegovy, announces $299 price","sentiment":"neutral"}],"patents":[{"drugName":"Victoza","drugSlug":"liraglutide","patentNumber":"8114833","type":"Formulation","expiryDate":"2025-08-13","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Victoza","drugSlug":"liraglutide","patentNumber":"8114833*PED","type":"Compound","expiryDate":"2026-02-13","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Victoza","drugSlug":"liraglutide","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":500000000},{"drugName":"Ozempic","drugSlug":"semaglutide","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1500000000},{"drugName":"Victoza","drugSlug":"liraglutide","patentNumber":"9968659","type":"Method of Use","expiryDate":"2037-01-09","territory":"US","annualRevenue":3200000000,"genericFilings":[]},{"drugName":"Victoza","drugSlug":"liraglutide","patentNumber":"9968659*PED","type":"Compound","expiryDate":"2037-07-09","territory":"US","annualRevenue":3200000000,"genericFilings":[]}],"drugCount":90,"phaseCounts":{"marketed":50,"phase_1":9,"phase_3":29,"phase_2":2},"enrichmentLevel":3,"visitCount":9,"keyCompetitors":["Sanofi","Eli Lilly","Merck & Co."],"therapeuticFocus":["Diabetes","Obesity Management"],"financials":{"source":"sec_edgar+yahoo","revenue":48297514727.28,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":48297514727.28},{"period":"2024-12-31","value":45381355218.81},{"period":"2023-12-31","value":36295489180.47},{"period":"2022-12-31","value":27652649357.579998}],"grossProfit":39110698094.52,"grossProfitHistory":[{"period":"2025-12-31","value":39110698094.52},{"period":"2024-12-31","value":38423890257.869995},{"period":"2023-12-31","value":30706482973.92},{"period":"2022-12-31","value":23207072716.62}],"rdSpend":8132148580.53,"rdSpendHistory":[{"period":"2025-12-31","value":8132148580.53},{"period":"2024-12-31","value":7510661716.74},{"period":"2023-12-31","value":5069876369.61},{"period":"2022-12-31","value":3757831182.6899996}],"sgaSpend":10982518305.33,"operatingIncome":19949150127.66,"operatingIncomeHistory":[{"period":"2025-12-31","value":19949150127.66},{"period":"2024-12-31","value":20055570181.53},{"period":"2023-12-31","value":16029266674.98},{"period":"2022-12-31","value":11690422628.429998}],"netIncome":16007388837.179998,"netIncomeHistory":[{"period":"2025-12-31","value":16007388837.179998},{"period":"2024-12-31","value":15781422026.759998},{"period":"2023-12-31","value":13077165004.41},{"period":"2022-12-31","value":8676906741.75}],"eps":23.03,"epsHistory":[{"period":"2025-12-31","value":23.03},{"period":"2024-12-31","value":22.63},{"period":"2023-12-31","value":18.62},{"period":"2022-12-31","value":12.22}],"cash":4135536425.2799997,"cashHistory":[{"period":"2025-12-31","value":4135536425.2799997},{"period":"2024-12-31","value":2446411076.85},{"period":"2023-12-31","value":2249041725.8399997},{"period":"2022-12-31","value":1977287726.31}],"totalAssets":84839442123.54,"totalLiabilities":54515665040.85,"totalDebt":20464842018.66,"equity":30323777082.69,"operatingCashflow":18612101697.539997,"operatingCashflowHistory":[{"period":"2025-12-31","value":18612101697.539997},{"period":"2024-12-31","value":18903702021.359997},{"period":"2023-12-31","value":17019082565.159998},{"period":"2022-12-31","value":12327692789.49}],"capex":-14081982840.509998,"capexHistory":[{"period":"2025-12-31","value":-14081982840.509998},{"period":"2024-12-31","value":-8018071283.429999},{"period":"2023-12-31","value":-6078288421.919999},{"period":"2022-12-31","value":-2305455293.31}],"freeCashflow":4530118857.03,"dividendsPaid":-8089017986.009999,"buybacks":-216903134.76,"employees":67900,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":2065424158.59,"ebit":10262424901.17,"ebitda":10814996575.89,"period":"2026-03-31","revenue":15130556352.21,"epsBasic":10.93,"netIncome":7588015500.389999,"rdExpense":1607083456.6799998,"epsDiluted":10.91,"grossProfit":13005593220.75,"operatingIncome":9316520956.859999},{"sga":2725040968.2599998,"ebit":4959393288.719999,"ebitda":5828568530.46,"period":"2025-12-31","revenue":12367854248.88,"epsBasic":6.06,"netIncome":4202263830.5699997,"rdExpense":2289046914.96,"epsDiluted":6.04,"grossProfit":10000672198.92,"operatingIncome":4959393288.719999},{"sga":2794112427.6,"ebit":3700792534.14,"ebitda":4912981018.53,"period":"2025-09-30","revenue":11716519763.519999,"epsBasic":4.5,"netIncome":3126343021.62,"rdExpense":2405468266.1099997,"epsDiluted":4.5,"grossProfit":8918656849.439999,"operatingIncome":3700792534.14},{"sga":2945538319.23,"ebit":6057504476.009999,"ebitda":6812758690.919999,"period":"2025-06-30","revenue":12010464141.39,"epsBasic":5.96,"netIncome":4141630965.81,"rdExpense":1826799456.3,"epsDiluted":5.96,"grossProfit":10003016252.97,"operatingIncome":5227084261.23},{"sga":2517826590.24,"ebit":6597105718.32,"ebitda":7195620852.419999,"period":"2025-03-31","revenue":12202676573.49,"epsBasic":6.54,"netIncome":4537151019.179999,"rdExpense":1610833943.1599998,"epsDiluted":6.53,"grossProfit":10188352793.189999,"operatingIncome":6061880043.57},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":46.12,"previousClose":47.08,"fiftyTwoWeekHigh":81.44,"fiftyTwoWeekLow":35.12,"fiftyTwoWeekRange":"35.12 - 81.44","fiftyDayAverage":39.72,"twoHundredDayAverage":49.2,"beta":0.35,"enterpriseValue":52180351734.62212,"forwardPE":13.6,"priceToBook":6.4,"priceToSales":0.62,"enterpriseToRevenue":1.02,"enterpriseToEbitda":1.92,"pegRatio":3.37,"ebitda":27171649906.57708,"ebitdaMargin":53,"freeCashflow":-1881376835.5958784,"operatingCashflow":18511151183.13038,"totalDebt":22875154043.059566,"debtToEquity":72.1,"currentRatio":0.79,"returnOnAssets":19.2,"returnOnEquity":71.4,"analystRating":"2.4 - Buy","recommendationKey":"buy","numberOfAnalysts":12,"targetMeanPrice":46.86,"targetHighPrice":64.48,"targetLowPrice":39.74,"dividendRate":1.8,"payoutRatio":0.43,"fiveYearAvgDividendYield":1.75,"exDividendDate":1774828800,"insiderHeldPercent":0,"institutionHeldPercent":9.7,"sharesOutstanding":3357979022,"floatShares":3186236594,"sharesShort":13996269,"shortRatio":0.83,"shortPercentOfFloat":0.3,"epsTrailing":4.32,"epsForward":3.39,"revenuePerShare":73.77,"bookValue":7.21,"officers":[{"age":54,"name":"Mr. Karsten Munk Knudsen","title":"Executive VP, CFO & Member of the Management Board"},{"age":55,"name":"Mr. Maziar Mike Doustdar B.A.","title":"President, CEO & Member of the Management Board"},{"age":55,"name":"Dr. Martin Holst Lange","title":"EVP of R&D, Chief Scientific Officer and Member of the Management Board"},{"age":48,"name":"Ms. Tania  Sabroe","title":"EVP of People, Organisation and Corporate Affairs & Member of Management Board"},{"age":43,"name":"Ms. Thilde Hummel Bogebjerg","title":"Executive VP of Enterprise IT & Quality and Member of Management Board"},{"age":53,"name":"Mr. John F. Kuckelman","title":"SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board"},{"age":50,"name":"Mr. Emil Kongshoej Larsen","title":"EVP of International Operations & Member of Management Board"},{"age":39,"name":"Ms. Elin  Jager","title":"SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board"}],"industry":"Drug Manufacturers - General","irWebsite":"http://www.novonordisk.com/investors/default.asp","website":"https://www.novonordisk.com","phone":"45 44 44 88 88"}}